ロード中...
The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
The use of immunotherapy to treat cancer is rapidly gaining momentum. Using pre-clinical mouse models, we have recently demonstrated potent and long lasting tumor regression can be elicited by immune-stimulating monoclonal antibodies (mAbs) when combined with histone deacetylase inhibitors (HDACi) a...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Landes Bioscience
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3382866/ https://ncbi.nlm.nih.gov/pubmed/22737621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.18804 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|